FluoroPharma Receives Patent on Metabolic Markers for PET and SPECT Imaging
Further Strengthening Company IP, Pipeline and Targets
(firmenpresse) - MONTCLAIR, NJ -- (Marketwire) -- 03/22/13 -- FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that it has received a patent covering a platform series of metabolic markers for PET and SPECT imaging. The compounds' specific use is for metabolic activity deficiencies in organs such as heart and liver as well as for tumor tissue activity.
Today's announcement enhances FluoroPharma's IP position and strengthens its growing patent estate, further validating the importance and value of FluoroPharma's technology in what management believes are important growth markets where diagnostic imaging is playing an increasingly significant role in the early detection of disease.
According to Thijs Spoor, Chairman, CEO and President of FluoroPharma Medical, "This addition to our patent portfolio allows us to continue our path towards enabling personalized medicine through precision diagnostics. We believe that allowing clinicians to observe and evaluate changes in the metabolic state of specific tissues and organs, may open up new areas of awareness of the clinical implications of altered tumor metabolism in diseases such as prostate cancer as well as other conditions associated with lipid metabolism in patients with metabolic disorders."
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.
The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease and agents that could potentially be used for imaging specific cancers.
In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.
For more information on the Company, please visit:
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Media:
Carol Perlman
FluoroPharma Medical, Inc.
Phone: 917-592-9260
Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Phone: 212-554-5466
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2013 - 11:30 Uhr
Sprache: Deutsch
News-ID 242240
Anzahl Zeichen: 0
contact information:
Town:
MONTCLAIR, NJ
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"FluoroPharma Receives Patent on Metabolic Markers for PET and SPECT Imaging"
steht unter der journalistisch-redaktionellen Verantwortung von
FluoroPharma Medical, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
